HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.

Abstract
Here we report that the N-pyridinylmethyl cyclam analog AMD3451 has antiviral activity against a wide variety of R5, R5/X4, and X4 strains of human immunodeficiency virus type 1 (HIV-1) and HIV-2 (50% inhibitory concentration [IC(50)] ranging from 1.2 to 26.5 microM) in various T-cell lines, CCR5- or CXCR4-transfected cells, peripheral blood mononuclear cells (PBMCs), and monocytes/macrophages. AMD3451 also inhibited R5, R5/X4, and X4 HIV-1 primary clinical isolates in PBMCs (IC(50), 1.8 to 7.3 microM). A PCR-based viral entry assay revealed that AMD3451 blocks R5 and X4 HIV-1 infection at the virus entry stage. AMD3451 dose-dependently inhibited the intracellular Ca(2+) signaling induced by the CXCR4 ligand CXCL12 in T-lymphocytic cells and in CXCR4-transfected cells, as well as the Ca(2+) flux induced by the CCR5 ligands CCL5, CCL3, and CCL4 in CCR5-transfected cells. The compound did not interfere with chemokine-induced Ca(2+) signaling through CCR1, CCR2, CCR3, CCR4, CCR6, CCR9, or CXCR3 and did not induce intracellular Ca(2+) signaling by itself at concentrations up to 400 microM. In freshly isolated monocytes, AMD3451 inhibited the Ca(2+) flux induced by CXCL12 and CCL4 but not that induced by CCL2, CCL3, CCL5, and CCL7. The CXCL12- and CCL3-induced chemotaxis was also dose-dependently inhibited by AMD3451. Furthermore, AMD3451 inhibited CXCL12- and CCL3L1-induced endocytosis in CXCR4- and CCR5-transfected cells. AMD3451, in contrast to the specific CXCR4 antagonist AMD3100, did not inhibit but enhanced the binding of several anti-CXCR4 monoclonal antibodies (such as clone 12G5) at the cell surface, pointing to a different interaction with CXCR4. AMD3451 is the first low-molecular-weight anti-HIV agent with selective HIV coreceptor, CCR5 and CXCR4, interaction.
AuthorsKatrien Princen, Sigrid Hatse, Kurt Vermeire, Stefano Aquaro, Erik De Clercq, Lars-Ole Gerlach, Mette Rosenkilde, Thue W Schwartz, Renato Skerlj, Gary Bridger, Dominique Schols
JournalJournal of virology (J Virol) Vol. 78 Issue 23 Pg. 12996-3006 (Dec 2004) ISSN: 0022-538X [Print] United States
PMID15542651 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 1-((2,6-dichloropyridin-4-yl)methyl)-1,4,8,11-tetrazacyclotetradecane
  • Anti-HIV Agents
  • Antibodies, Monoclonal
  • CCL3L1 protein, human
  • CCR5 Receptor Antagonists
  • CXCL12 protein, human
  • Chemokine CXCL12
  • Chemokines, CC
  • Chemokines, CXC
  • Heterocyclic Compounds
  • Pyridines
  • Receptors, CXCR4
  • Calcium
Topics
  • Anti-HIV Agents (pharmacology)
  • Antibodies, Monoclonal (immunology)
  • CCR5 Receptor Antagonists
  • Calcium (metabolism)
  • Chemokine CXCL12
  • Chemokines, CC (antagonists & inhibitors)
  • Chemokines, CXC (antagonists & inhibitors)
  • Chemotaxis (drug effects)
  • HIV (drug effects, physiology)
  • Heterocyclic Compounds (pharmacology)
  • Humans
  • Pyridines (pharmacology)
  • Receptors, CXCR4 (antagonists & inhibitors)
  • Virus Replication (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: